supported by the Beijing Municipal Administration of Hospitals’Ascent Plan(No.DFL20191802);Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support(No.ZYLX202126);Capital’s Funds for Health Improvement and Research(No.2020-2-2174)
Background:This study aimed to determine the reasons for conversion and elucidate the safety and efficacy of transition to tenofovir alafenamide/emtricitabine/bictegravir sodium(TAF/FTC/BIC)in highly active antiretrov...